ArQule Company Profile (NASDAQ:ARQL)

About ArQule (NASDAQ:ARQL)

ArQule logoArQule, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations. The Company's lead product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase (MET) and its biological pathway. The Company's product candidates include ARQ 092, designed to inhibit the AKT serine/threonine kinase; ARQ 087, a multi-kinase inhibitor designed to inhibit the fibroblast growth factor receptor (FGFR) family, and ARQ 761, a Beta lapachone analog being evaluated in investigator-sponsored testing as a promoter of NQO1-mediated programmed cancer cell necrosis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ARQL
  • CUSIP: 04269E10
  • Web:
  • Market Cap: $91.07 million
  • Outstanding Shares: 71,146,000
Average Prices:
  • 50 Day Moving Avg: $1.21
  • 200 Day Moving Avg: $1.22
  • 52 Week Range: $0.92 - $1.82
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.12
  • P/E Growth: -0.59
Sales & Book Value:
  • Annual Revenue: $3.48 million
  • Price / Sales: 26.17
  • Book Value: $0.24 per share
  • Price / Book: 5.33
  • EBIDTA: ($25,050,000.00)
  • Net Margins: -482.44%
  • Return on Equity: -95.33%
  • Return on Assets: -66.00%
  • Debt-to-Equity Ratio: 0.84%
  • Current Ratio: 5.33%
  • Quick Ratio: 5.33%
  • Average Volume: 135,778 shs.
  • Beta: 1.48
  • Short Ratio: 9.07

Frequently Asked Questions for ArQule (NASDAQ:ARQL)

What is ArQule's stock symbol?

ArQule trades on the NASDAQ under the ticker symbol "ARQL."

How were ArQule's earnings last quarter?

ArQule, Inc. (NASDAQ:ARQL) announced its quarterly earnings data on Wednesday, May, 3rd. The company reported ($0.11) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.00. ArQule had a negative net margin of 482.44% and a negative return on equity of 95.33%. During the same period in the prior year, the company posted ($0.08) earnings per share. View ArQule's Earnings History.

When will ArQule make its next earnings announcement?

ArQule is scheduled to release their next quarterly earnings announcement on Tuesday, August, 1st 2017. View Earnings Estimates for ArQule.

Who are some of ArQule's key competitors?

Who are ArQule's key executives?

ArQule's management team includes the folowing people:

  • Patrick J. Zenner, Independent Chairman of the Board
  • Peter S. Lawrence, President, Chief Operating Officer
  • Paolo Pucci, Chief Executive Officer, Director
  • Robert J. Weiskopf, Chief Financial Officer, Treasurer
  • Brian Schwartz M.D., Chief Medical Officer
  • Timothy C. Barabe, Independent Director
  • Susan L. Kelley M.D., Independent Director
  • Ronald M. Lindsay Ph.D., Independent Director
  • Michael D. Loberg Ph.D., Independent Director
  • William G. Messenger D. Min., Independent Director

How do I buy ArQule stock?

Shares of ArQule can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ArQule's stock price today?

One share of ArQule stock can currently be purchased for approximately $1.28.

MarketBeat Community Rating for ArQule (NASDAQ ARQL)
Community Ranking:  2.3 out of 5 ( )
Outperform Votes:  59 (Vote Outperform)
Underperform Votes:  70 (Vote Underperform)
Total Votes:  129
MarketBeat's community ratings are surveys of what our community members think about ArQule and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ArQule (NASDAQ:ARQL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for ArQule (NASDAQ:ARQL)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/1/2016Leerink SwannLower Price TargetMarket Perform$3.00 -> $2.50N/AView Rating Details
12/27/2015Royal Bank Of CanadaUpgradeBuyN/AView Rating Details
(Data available from 7/21/2015 forward)


Earnings History for ArQule (NASDAQ:ARQL)
Earnings by Quarter for ArQule (NASDAQ:ARQL)
Earnings History by Quarter for ArQule (NASDAQ ARQL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2017($0.11)N/AView Earnings Details
5/3/2017Q1 2017($0.11)($0.11)ViewListenView Earnings Details
3/7/2017Q4 2016($0.10)($0.10)$1.20 million$1.19 millionViewListenView Earnings Details
11/7/2016Q316($0.09)($0.08)$1.10 million$1.22 millionViewListenView Earnings Details
8/3/2016Q216($0.08)($0.07)$1.13 million$1.07 millionViewN/AView Earnings Details
5/4/2016Q116($0.07)($0.08)$1.63 million$1.28 millionViewN/AView Earnings Details
2/29/2016Q415($0.06)($0.05)$2.40 million$2.80 millionViewListenView Earnings Details
11/4/2015Q315($0.08)($0.04)$2.60 million$2.65 millionViewN/AView Earnings Details
8/5/2015Q215($0.08)($0.06)$2.50 million$3.04 millionViewN/AView Earnings Details
5/6/2015Q115($0.08)($0.07)$1.98 million$2.79 millionViewN/AView Earnings Details
3/4/2015Q414($0.13)($0.06)$1.90 million$3.02 millionViewN/AView Earnings Details
11/10/2014Q314($0.13)($0.10)$2.20 million$2.66 millionViewN/AView Earnings Details
8/5/2014Q214($0.13)($0.10)$2.43 million$2.90 millionViewN/AView Earnings Details
5/7/2014Q114($0.11)($0.11)$2.29 million$2.67 millionViewN/AView Earnings Details
3/5/2014Q413($0.13)($0.10)$2.27 million$2.28 millionViewN/AView Earnings Details
10/31/2013Q313($0.13)($0.10)$2.77 million$3.50 millionViewN/AView Earnings Details
7/30/2013Q2 2013($0.12)($0.11)$3.84 million$4.44 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.11)($0.09)$3.78 million$5.66 millionViewN/AView Earnings Details
3/14/2013Q4 2012($0.13)($0.09)$5.17 million$5.14 millionViewN/AView Earnings Details
11/1/2012($0.07)($0.01)ViewN/AView Earnings Details
8/2/2012($0.07)($0.01)ViewN/AView Earnings Details
5/3/2012($0.07)($0.08)ViewN/AView Earnings Details
3/1/2012($0.09)$0.07ViewN/AView Earnings Details
11/10/2011($0.23)($0.04)ViewN/AView Earnings Details
8/4/2011($0.19)($0.20)ViewN/AView Earnings Details
5/5/2011($0.08)($0.03)ViewN/AView Earnings Details
3/1/2011($0.15)($0.13)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for ArQule (NASDAQ:ARQL)
2017 EPS Consensus Estimate: ($0.45)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.10)($0.10)($0.10)
Q2 20171($0.11)($0.11)($0.11)
Q3 20171($0.12)($0.12)($0.12)
Q4 20171($0.12)($0.12)($0.12)
(Data provided by Zacks Investment Research)


Dividend History for ArQule (NASDAQ:ARQL)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for ArQule (NASDAQ:ARQL)
Insider Ownership Percentage: 9.00%
Institutional Ownership Percentage: 60.55%
Insider Trades by Quarter for ArQule (NASDAQ:ARQL)
Institutional Ownership by Quarter for ArQule (NASDAQ:ARQL)
Insider Trades by Quarter for ArQule (NASDAQ:ARQL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/17/2015Michael D LobergDirectorBuy3,719$2.16$8,033.04View SEC Filing  
12/16/2015Michael D LobergDirectorBuy1,231$2.14$2,634.34View SEC Filing  
12/15/2015Paolo PucciCEOBuy1,283$2.16$2,771.28View SEC Filing  
12/11/2015Paolo PucciCEOBuy1,108$2.10$2,326.80View SEC Filing  
12/11/2015Patrick J ZennerDirectorBuy2,300$2.15$4,945.00View SEC Filing  
12/10/2015Paolo PucciCEOBuy7,609$2.10$15,978.90View SEC Filing  
3/11/2015Patrick J ZennerDirectorBuy10,625$2.32$24,650.00View SEC Filing  
11/20/2014Paolo PucciCEOBuy5,000$1.26$6,300.00View SEC Filing  
11/14/2014Patrick J ZennerDirectorBuy20,830$1.20$24,996.00View SEC Filing  
11/13/2014Susan L KelleyDirectorBuy50,000$1.20$60,000.00View SEC Filing  
9/4/2014Paolo PucciCEOBuy5,000$1.31$6,550.00View SEC Filing  
5/23/2014Paolo PucciCEOBuy5,000$1.40$7,000.00View SEC Filing  
5/20/2014Paolo PucciCEOBuy5,000$1.42$7,100.00View SEC Filing  
3/17/2014Patrick ZennerDirectorBuy4,715$2.12$9,995.80View SEC Filing  
3/13/2014Paolo PucciCEOBuy10,000$2.10$21,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for ArQule (NASDAQ:ARQL)
Latest Headlines for ArQule (NASDAQ:ARQL)
DateHeadline logoArQule: First Patient Dosed In ARQ 531 Phase 1 Trial For B-cell Malignancies - July 12 at 1:40 AM logoArQule Announces First Patient Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies - July 11 at 3:38 PM logoSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating ArQule, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors - June 26 at 4:08 PM logoArQule (ARQL) Presents Preclinical Data for BTK Inhibitor, ARQ 531, at EHA - June 24 at 8:48 PM logoArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA) - June 23 at 4:15 PM logoArQule Announces First Patient Dosed in Company Sponsored Phase 1/2 Trial of AKT Inhibitor, ARQ 092, for Rare Overgrowth Diseases - June 7 at 3:50 PM logo Analysts Expect ArQule, Inc. (ARQL) to Announce -$0.11 EPS - June 5 at 7:37 AM logoArQule Presents Phase 1/2 Clinical Data with ARQ 087 in Intrahepatic Cholangiocarcinoma at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting - June 3 at 3:40 PM logoArQule Presents Phase 1/2 Clinical Data with ARQ 087 in Intrahepatic Cholangiocarcinoma at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting - June 3 at 3:40 PM logoArQule Stock Up 28% on Lab Data for B-Cell Lymphoma Drug - May 19 at 9:27 AM logoArQule to Present Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA) - May 18 at 12:06 PM logoArQule to Present Clinical Data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting - May 17 at 8:40 PM logoArQule, Inc. (ARQL) Short Interest Update - May 15 at 8:48 AM logo-$0.11 EPS Expected for ArQule, Inc. (ARQL) This Quarter - May 9 at 6:16 PM logoLeerink Swann Brokers Cut Earnings Estimates for ArQule, Inc. (ARQL) - May 8 at 8:26 AM logoArQule, Inc. (ARQL) Downgraded to "Sell" at Zacks Investment Research - May 4 at 7:06 PM logoEdited Transcript of ARQL earnings conference call or presentation 3-May-17 1:00pm GMT - May 4 at 1:47 AM logoArQule, Inc. (ARQL) Issues Earnings Results, Meets Expectations - May 3 at 12:33 PM logoArqule Reports First Quarter 2017 Financial Results - May 3 at 9:55 AM logoArQule reports 1Q loss - May 3 at 9:55 AM logoInvestor Network: ArQule, Inc. to Host Earnings Call - May 3 at 9:55 AM logoArQule (ARQL) Earns Daily Media Impact Rating of 0.13 - May 2 at 8:16 AM logoArQule, Inc. (ARQL) Scheduled to Post Earnings on Wednesday - May 1 at 11:56 AM logoArQule (ARQL) Receiving Somewhat Favorable News Coverage, Report Shows - April 27 at 4:38 PM logoArQule Announces Issuance of U.S. Patent Covering Composition of Matter of Proprietary Reversible BTK Inhibitor, ARQ 531 - April 26 at 9:10 AM logoArQule (ARQL) Earning Somewhat Positive Press Coverage, Report Finds - April 20 at 2:42 PM logoArQule To Report First Quarter 2017 Financial Results On May 3, 2017 - April 19 at 9:15 AM logo-$0.10 EPS Expected for ArQule, Inc. (ARQL) This Quarter - April 18 at 10:21 PM logoSomewhat Favorable Media Coverage Somewhat Likely to Impact ArQule (ARQL) Stock Price - April 17 at 12:07 PM logoSomewhat Critical Press Coverage Somewhat Likely to Effect ArQule (ARQL) Share Price - April 14 at 7:58 AM logoArQule (ARQL) Announces IND Application for BTK Inhibitor ARQ 531 Cleared by FDA - - April 11 at 8:03 AM logoArQule Receives Clearance of Investigational New Drug Application from the FDA for Proprietary Reversible BTK Inhibitor, ARQ 531 - April 11 at 8:03 AM logoETFs with exposure to ArQule, Inc. : April 5, 2017 - April 7 at 8:07 AM logoFDA Nod For TSRO, Déjà Vu For ARQL, FOMX Plunges On Trial Data, SELB Abuzz - RTT News - March 28 at 3:38 PM logoArQule to Present at the 16th Annual Needham Healthcare Conference on April 4, 2017 - March 28 at 10:32 AM logoPre-Open Movers 03/27: (HTGM) (WFT) (SNAP) Higher; (FOMX) (ARQL) (MEET) Lower (more...) - March 27 at 3:42 PM logoArQule Announces Top-Line Results of Phase 3 Clinical Study of Tivantinib in Hepatocellular Carcinoma in Japan - March 27 at 8:30 AM logoZacks: ArQule, Inc. (ARQL) Given $1.30 Consensus Price Target by Analysts - March 23 at 10:43 AM logoARQULE INC Financials - March 15 at 3:54 PM logoARQULE INC Files SEC form 10-K, Annual Report - March 9 at 9:15 PM logoEdited Transcript of ARQL earnings conference call or presentation 7-Mar-17 2:00pm GMT - March 8 at 1:41 AM logoEARNINGS SUMMARY: Details of ArQule Inc. Q4 Earnings Report - March 7 at 3:40 PM logoArQule's (ARQL) CEO Paolo Pucci on Q4 2016 Results - Earnings Call Transcript - March 7 at 3:40 PM logoArQule Reports Fourth Quarter and Full Year 2016 Financial Results - March 7 at 3:40 PM logoQ4 2016 ArQule Inc Earnings Release - Before Market Open - March 7 at 3:40 PM logoARQULE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits - March 7 at 8:28 AM logoArQule To Report Fourth Quarter and Year End 2016 Financial Results On March 7, 2017 - February 24 at 12:37 PM logoArQule Liver Cancer Drug Fails Phase 3 (ARQL) - February 20 at 3:32 PM logoArQule Liver Cancer Drug Fails Phase 3 Trial - February 20 at 3:32 PM logoArQule (ARQL), Daiichi Sankyo Phase 3 Study of Tivantinib Misses ... - - February 18 at 3:35 PM



ArQule (ARQL) Chart for Friday, July, 21, 2017

This page was last updated on 7/21/2017 by Staff